These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37551607)

  • 21. Managing dissociative symptoms following the use of esketamine nasal spray: a case report.
    Pereira S; Brennan E; Patel A; Moran M; Wallier J; Liebowitz MR
    Int Clin Psychopharmacol; 2021 Jan; 36(1):54-57. PubMed ID: 32804743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new indication for esketamine nasal spray (Spravato).
    Med Lett Drugs Ther; 2020 Sep; 62(1607):151. PubMed ID: 32960869
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
    BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
    Santucci MC; Ansari M; Nikayin S; Radhakrishnan R; Rhee TG; Wilkinson ST
    J Clin Psychiatry; 2024 Oct; 85(4):. PubMed ID: 39361411
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
    J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
    Zaki N; Chen LN; Lane R; Doherty T; Drevets WC; Morrison RL; Sanacora G; Wilkinson ST; Popova V; Fu DJ
    Neuropsychopharmacology; 2023 Jul; 48(8):1225-1233. PubMed ID: 37173512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.
    Canuso CM; Ionescu DF; Li X; Qiu X; Lane R; Turkoz I; Nash AI; Lopena TJ; Fu DJ
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):516-524. PubMed ID: 34412104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esketamine Nasal Spray for Treatment-Resistant Depression.
    Fantasia HC
    Nurs Womens Health; 2020 Jun; 24(3):228-232. PubMed ID: 32387141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Esketamine among patients with treatment resistant depression in a 'real world' health-care setting in Israel.
    Dvorak L; Bloemhof-Bris E; Shelef A; Halperin D; Wexler G; Talmon O; Feffer K
    J Psychiatr Res; 2024 Jun; 174():66-72. PubMed ID: 38626563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compounded intranasal racemic ketamine for major depressive disorder: A case report.
    Ziegler L; Peters E; Wanson A; Halpape K
    Exp Clin Psychopharmacol; 2021 Dec; 29(6):750-754. PubMed ID: 33661659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
    Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G
    Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.
    Teeple A; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Joshi K
    Curr Med Res Opin; 2023 Aug; 39(8):1167-1174. PubMed ID: 37492015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
    Seshadri A; Prokop LJ; Singh B
    J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.
    Harding L; Zhdanava M; Shah A; Pesa J; Totev TI; Tardif-Samson A; Pilon D; Joshi K
    Curr Med Res Opin; 2024 Sep; 40(9):1615-1623. PubMed ID: 39034772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.